[1] Also known as remestemcel-L, Prochymal was sold to Australia-based Mesoblast in 2013[2] at which time its brand name was changed to Ryoncil.
MSCs are purified from the marrow, cultured and packaged, with up to 10,000 doses derived from a single donor.
[1][5] Separately, a pilot study of Ryoncil on ventilator-assisted COVID-19 patients with Acute Respiratory Distress Syndrome provided sufficient evidence for the FDA to approve a Phase 2/3 placebo-controlled trial on 300 patients.
It is being overseen by Mount Sinai Hospital and the Cardiothoracic Clinical Trials Network and funded by the National Institutes of Health.
[6] Preliminary results of a phase III trial for GvHD were released in Sept 2009.